1125-41-3

Basic information

• Product Name: 5-CHLORO-3-METHYLBENZOFURAN
• Synonyms: 5-CHLORO-3-METHYLBENZOFURAN;Benzofuran, 5-chloro-3-Methyl-
• CAS NO: 1125-41-3
• Molecular Formula: C9H7ClO
• Molecular Weight: 166.6
• Mol File: 1125-41-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 232-233 °C
• Appearance: /
• Density: 1.238±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 5-CHLORO-3-METHYLBENZOFURAN(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-3-METHYLBENZOFURAN(1125-41-3)
• EPA Substance Registry System: 5-CHLORO-3-METHYLBENZOFURAN(1125-41-3)

Safety Data

• Hazardous Substances Data: 1125-41-3(Hazardous Substances Data)

Usage

Uses

5-Chloro-3-methylbenzofuran are commonly involved with ?Palladium(II)-Catalyzed reactions.

Upstream product

• 100119-57-1 (2-acetyl-4-chlorophenoxy)acetic acid ethyl ester 
• 463976-07-0 6-(5-Chloro-3-methyl-benzofuran-2-sulfonyl)-2H-Pyridazin-3-one 
• 21758-94-1 (2-acetyl-4-chlorophenoxy)acetic acid 

Downstream Products

• 463976-07-0 6-(5-Chloro-3-methyl-benzofuran-2-sulfonyl)-2H-Pyridazin-3-one 

Relevant articles and documents

Pyridazinone aldose reductase inhibitors

The present invention relates to novel pyridazinone compounds, pharmaceutical compositions comprising those compounds and to methods of using such compounds and compositions to inhibit aldose reductase, lower sorbitol levels and, thus, lower fructose levels, and/or treat or prevent diabetic complications such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic microangiopathy and diabetic macroangiopathy in mammals. This invention also relates to methods of affording cardioprotection to subjects not suffering from diabetes. This invention also relates to pharmaceutical compositions and kits comprising a combination of an aldose reductase inhibitor (ARI) of this invention and a sorbitol dehydrogenase inhibitor and to methods of using such compositions or kits to treat or prevent the above diabetic complications in mammals. This invention also relates to other combinations with the ARIs of this invention, including combinations with adendsine agonists; NHE-1 inhibitors; glycogen phosphorylase inhibitors; selective serotonin reuptake inhibitors; GABA agonists; antihypertensive agents; 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors; phosphodiesterase-5 inhibitors; and to glucose lowering agents.

BENZOFURAN DERIVATIVES. I. ON THE EFFECTS OF SUBSTITUENTS IN BENZOFURAN SYNTHESES.

The Roessing's reaction of 4-substituted 2-acylphenoxyacetic acids give a mixture of benzofurans and 2-benzofurancarboxylic acids. The relative yields of benzofurans and 2-benzofurancarboxylic acids depend on the substituents on the benzene ring of the 2-acylphenoxyacetic acids. Electron-withdrawing substituents such as nitro groups favor the formation of 2-benzofurancarboxylic acids. On the other hand, the formation of benzofurans is favored by the steric hindrance of 2-acyl groups in the reaction of 2-acyl-4-nitrophenoxyacetic acids with anhydrous sodium acetate and acetic anhydride.